Invision Diagnostics adds CureMetrix AI breast imaging tool to mobile mammography

Invision Diagnostics is adding CureMetrix’s cmAngio to its mobile mammography services, expanding access to AI-powered breast imaging across the Southeast. The move gives providers Breast Arterial Calcification detection from routine screening exams without extra imaging or radiation.

Why it matters: - Invision Diagnostics is broadening the value of routine mammograms by adding an FDA-cleared AI tool that can detect and localize Breast Arterial Calcifications. - The addition gives providers another clinical signal from the same screening exam used for breast cancer detection. - The move could expand access to enhanced breast imaging for women in mobile screening settings, including communities that may not have easy access to fixed imaging centers.

What happened: - Invision Diagnostics added CureMetrix’s cmAngio to its service offerings. - The mobile mammography provider operates seven days a week. - The service reaches women where they live and work across North Carolina, South Carolina, Florida and other Southeast communities. - The collaboration expands access to AI-powered breast imaging through mobile mammography units.

The details: - cmAngio is the first FDA-cleared AI solution for Breast Arterial Calcification detection and localization. - The technology lets providers get more from routine mammography without additional imaging, radiation or procedures. - Invision Diagnostics said the addition supports providers with added clinical insight from routine mammography while advancing access to high-quality breast care. - CureMetrix said the partnership combines its technology with Invision Diagnostics’ mobile access model to help providers deliver more insight from mammograms women already receive. - Invision Diagnostics’ screening-driven mobile model now links to a network of more than 400 imaging sites using the technology. - The company says that scale extends clinical insight through high-volume screening services. - Imaging providers working with Invision Diagnostics will have access to cmAngio technology through the collaboration.

Between the lines: - The partnership reflects a broader push to turn standard breast screening into a more informative exam without changing the patient experience. - Mobile mammography remains the distribution channel here, which matters because access can be as important as the technology itself. - The combination of FDA clearance and a growing site network could make cmAngio easier for providers to adopt at scale.

What's next: - Imaging providers using Invision Diagnostics’ mobile services can begin offering cmAngio-enabled screening insight. - CureMetrix and Invision Diagnostics are positioning the collaboration as part of a wider effort to improve women’s health through expanded screening access. - Both companies say the goal is to deliver earlier answers and greater certainty from breast imaging workflows.

The bottom line: - Invision Diagnostics is using mobile mammography to extend the reach of CureMetrix’s AI breast imaging tool, aiming to give providers more information from the same screening exam. More information is available at Invision Diagnostics and CureMetrix.